| 刘杞梓,杨雪,徐鹏,秦倩倩,汤后林.HIV暴露前预防药物的研究进展[J].中华流行病学杂志,2022,43(12):2036-2040 |
| HIV暴露前预防药物的研究进展 |
| Research advances in HIV pre-exposure prophylaxis drug |
| 收稿日期:2022-07-05 出版日期:2022-12-17 |
| DOI：10.3760/cma.j.cn112338-20220705-00598 |
| 中文关键词: 艾滋病病毒 口服 暴露前预防 长效 抗病毒药物 |
| 英文关键词: HIV Oral Pre-exposure prophylaxis Long-acting Antiretroviral drug |
| 基金项目:国家自然科学基金（71874168） |
|
| 摘要点击次数: 1423 |
| 全文下载次数: 610 |
| 中文摘要: |
| 2012 年WHO发布了将替诺福韦/恩曲他滨（TDF/FTC）作为HIV暴露前预防（PrEP）药物用于降低特定人群中HIV感染风险，各类临床试验及真实世界的数据均证实了TDF/FTC在预防HIV感染方面的有效性。2019年，丙酚替诺福韦/恩曲他滨（TAF/FTC）在美国获得批准，成为第二个可用于PrEP口服药物。然而，对于不能口服药物或服用依从性较差的人群，第二代PrEP药物即长效抗病毒药物为其提供较多选择。本文综述第一代PrEP口服药物和近年研发的第二代PrEP药物的研究进展，为我国推广PrEP提供参考。 |
| 英文摘要: |
| In 2012, the World Health Organization (WHO) released tenofovir/emtricitabine (TDF/FTC) as pre-exposure prophylaxis drug to help people at risk of HIV infection in specific populations, and various clinical trials and real-world data have confirmed the effectiveness of TDF/FTC in preventing HIV infection. In 2019, propofol tenofovir combined with emtricitabine (TAF/FTC) was approved in the United States as the second oral drug for pre-exposure prophylaxis(PrEP). However, for people who cannot take the drug or have poor adherence to the drug, second-generation PrEP, or long-acting antiretrovirals, provide more options. This artical reviewed the research progress of the first generation of oral PrEP and the new PrEP developed in recent years to provide reference for the promotion of HIV PrEP in China. |
|
查看全文
Html全文
查看/发表评论 下载PDF阅读器 |
|
| 关闭 |
